氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照

Evaluation of Efficacy and Safety Control of Amisulpride and Risperidone in the Treatment of Schizophrenia

目的探究氨磺必利及利培酮治疗首发精神分裂症的治疗效果及用药安全。方法选取我院收治的86例首发精神分裂症患者作为研究对象,入选时间为2014年3月—2016年3月,按随机数字表法,将其分为两组,每组各43例;对照组给予利培酮治疗,观察组给予氨磺必利治疗,对比两组患者的治疗有效率、PANSS评分、TESS评分及用药不良反应发生率。结果观察组患者的治疗有效率、PANSS评分、TESS评分以及不良反应发生率均优于对照组,两组数据比较,差异具有统计学意义(P<0.05)。结论在治疗首发精神分裂症患者的过程中,实行氨磺必利与利培酮治疗效果显著,能明显改善患者临床症状降低用药不良反应发生率。

Objective To investigate the efficacy and safety of ammonia sulfonate and risperidone in the treatment of first-episode schizophrenia.Methods 86 cases of first-episode schizophrenics in our hospital were selected as the research subjects.The time of admission was from March 2014 to March 2016.According to the random number table method,it was divided into two groups,43 cases in each group.The control group was treated with risperidone.The observation group were given amisulpride treatment.The effective rate,PANSS score,TESS score and incidence of adverse drug reactions were compared between the two groups.Results The treatment efficiency,PANSS score,TESS score and the incidence of adverse reactions in the observation group were better than those in the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion In the treatment of first episode schizophrenic patients,the treatment effect of amisapride and risperidone is significant,and it can obviously improve the patients'clinical symptoms and reduce the incidence of adverse drug reactions.